Shield Therapeutics (LON:STX) Shares Up 1.6% – What’s Next?

Shield Therapeutics plc (LON:STX)’s stock price shot up 1.6% during mid-day trading on Wednesday . The company traded as high as GBX 9.70 and last traded at GBX 9.50. 448,511 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 2,006,339 shares. The stock had previously closed at GBX 9.35.

Shield Therapeutics Trading Up 1.6%

The firm has a market capitalization of £101.46 million, a PE ratio of -4.75 and a beta of 1.92. The company’s 50-day simple moving average is GBX 8.99 and its 200 day simple moving average is GBX 9.18. The company has a quick ratio of 2.16, a current ratio of 0.90 and a debt-to-equity ratio of -199.87.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.